A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Novartis
Carisma Therapeutics Inc
Pfizer
Novartis
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
Novartis
National Institutes of Health Clinical Center (CC)
Santa Maria Biotherapeutics
Ontario Clinical Oncology Group (OCOG)
Merck Sharp & Dohme LLC